Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company’s product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma. In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Metrics to compare | SNTI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSNTIPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.8x | −2.4x | −0.5x | |
PEG Ratio | −0.02 | −0.01 | 0.00 | |
Price/Book | 1.2x | 1.2x | 2.6x | |
Price / LTM Sales | - | 6.7x | 3.2x | |
Upside (Analyst Target) | - | 207.7% | 45.7% | |
Fair Value Upside | Unlock | 37.8% | 8.6% | Unlock |